BRAF: A New Target to Treat in Lung Cancer

GRACE Videos and Articles

ASCO 2015 Highlights 12

 

A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.

[powerpress]

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Comments

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation